NEW YORK (GenomeWeb) – Inflammatix, a startup spawned from a Stanford University research lab, seeks to measure gene expression patterns of a patient's immune response as a way to diagnose infectious disease.

In particular, Inflammatix anticipates that its first product will be a sepsis diagnostic — an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection so that physicians will be able to administer more appropriate treatments earlier.